Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17682-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- AHNAK2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated AHNAK2 antibody (Cat. #17682-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-MET.
Inhibition of AHNAK nucleoprotein 2 alleviates pulmonary fibrosis by downregulating the TGF-β1/Smad3 signaling pathway.
The AHNAK induces increased IL-6 production in CD4+ T cells and serves as a potential diagnostic biomarker for recurrent pregnancy loss.
AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
AHNAK2 Promotes Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the TGF-β/Smad3 Pathway.
Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.
Chen Z, Miao P, Lin H, Lu Y
Cancer management and research 2024;16:431-444
Cancer management and research 2024;16:431-444
Inhibition of AHNAK nucleoprotein 2 alleviates pulmonary fibrosis by downregulating the TGF-β1/Smad3 signaling pathway.
Zhu D, Zhang Q, Li Q, Wang G, Guo Z
The journal of gene medicine 2022 Sep;24(9):e3442
The journal of gene medicine 2022 Sep;24(9):e3442
The AHNAK induces increased IL-6 production in CD4+ T cells and serves as a potential diagnostic biomarker for recurrent pregnancy loss.
Li L, Liu Y, Feng T, Zhou W, Wang Y, Li H
Clinical and experimental immunology 2022 Sep 29;209(3):291-304
Clinical and experimental immunology 2022 Sep 29;209(3):291-304
AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
Zheng L, Li S, Zheng X, Guo R, Qu W
International immunopharmacology 2021 Jan;90:107185
International immunopharmacology 2021 Jan;90:107185
Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H, Zhao C, Yang Z, Shi J, Liu Y
International immunopharmacology 2021 Jan;90:107134
International immunopharmacology 2021 Jan;90:107134
AHNAK2 Promotes Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the TGF-β/Smad3 Pathway.
Liu G, Guo Z, Zhang Q, Liu Z, Zhu D
OncoTargets and therapy 2020;13:12893-12903
OncoTargets and therapy 2020;13:12893-12903
Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.
Ohmura H, Ito M, Uchino K, Okada C, Tanishima S, Yamada Y, Momosaki S, Komoda M, Kuwayama M, Yamaguchi K, Okumura Y, Nakano M, Tsuchihashi K, Isobe T, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E
FEBS open bio 2020 Jan;10(1):147-157
FEBS open bio 2020 Jan;10(1):147-157
No comments: Submit comment
No validations: Submit validation data